Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 54

1.

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, Assouline S, Kim TM, Kim WS, Ozcan M, Hirata J, Penuel E, Paulson JN, Cheng J, Ku G, Matasar MJ.

J Clin Oncol. 2019 Nov 6:JCO1900172. doi: 10.1200/JCO.19.00172. [Epub ahead of print]

PMID:
31693429
2.

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.

Armand P, Rodig S, Melnichenko V, Thieblemont C, Bouabdallah K, Tumyan G, Özcan M, Portino S, Fogliatto L, Caballero MD, Walewski J, Gulbas Z, Ribrag V, Christian B, Perini GF, Salles G, Svoboda J, Zain J, Patel S, Chen PH, Ligon AH, Ouyang J, Neuberg D, Redd R, Chatterjee A, Balakumaran A, Orlowski R, Shipp M, Zinzani PL.

J Clin Oncol. 2019 Dec 1;37(34):3291-3299. doi: 10.1200/JCO.19.01389. Epub 2019 Oct 14.

PMID:
31609651
3.

A Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experience

Çekdemir D, Güvenç S, Özdemirkıran F, Eser A, Toptaş T, Özkocaman V, Haydaroğlu Şahin H, Ermiş Turak E, Esen R, Cömert M, Sadri S, Aslaner M, Uncu Ulu B, Karakuş A, Selim Bapur D, Alacacıoğlu İ, Aydın D, Tekinalp A, Namdaroğlu S, Ceran F, Tarkun P, Kiper D, Çetiner M, Yenerel M, Demir AM, Yılmaz G, Terzi H, Atilla E, Malkan ÜY, Acar K, Öztürk E, Tombak A, Sunu C, Salim O, Alayvaz N, Sayan Ö, Ozan Ü, Ayer M, Gökgöz Z, Andıç N, Kızılkılıç E, Noyan F, Özen M, Pepedil Tanrıkulu F, Alanoğlu G, Özkan HA, Aslan V, Çetin G, Akyol Erikçi A, Deveci B, Ersoy Dursun F, Dermenci H, Aytan P, Gündüz M, Karakuş V, Özlü C, Demircioğlu S, Akay Yanar OM, Özatlı D, Ündar L, Tiftik EN, Türköz Sucak AG, Haznedaroğlu İ, Özcan M, Şencan M, Tombuloğlu M, Özet G, Bilgir O, Turgut B, Özcan MA, Payzın KB, Sönmez M, Ayyıldız O, Dal MS, Ertop Ş, Turgut M, Soysal T, Kaya E, Ünal A, Pehlivan M, Atagündüz I, Tuğlular Fıratlı T, Saydam G, Diz Küçükkaya R.

Turk J Haematol. 2019 Nov 18;36(4):230-237. doi: 10.4274/tjh.galenos.2019.2018.0307. Epub 2019 Jul 22.

4.

Severe Bone Marrow Hypoplasia with Black Cumin (Nigella sativa) Ingestion in a Patient with T-ALL in First Complete Remission

Narlı Özdemir Z, Öztürk C, Kuzu I, Özcan M.

Turk J Haematol. 2019 Aug 2;36(3):215-217. doi: 10.4274/tjh.galenos.2019.2019.0093. Epub 2019 Jun 14. No abstract available.

5.

Neutropenic fever and stem cell mobilization.

Topcuoglu P, Ozcan M.

J Clin Apher. 2019 Aug;34(4):517-518. doi: 10.1002/jca.21688. Epub 2019 Feb 19. No abstract available.

PMID:
30779434
6.

Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.

O'Connor OA, Özcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, Beaven A, Caballero D, Horwitz SM, Lennard A, Turgut M, Hamerschlak N, d'Amore FA, Foss F, Kim WS, Leonard JP, Zinzani PL, Chiattone CS, Hsi ED, Trümper L, Liu H, Sheldon-Waniga E, Ullmann CD, Venkatakrishnan K, Leonard EJ, Shustov AR; Lumiere Study Investigators.

J Clin Oncol. 2019 Mar 10;37(8):613-623. doi: 10.1200/JCO.18.00899. Epub 2019 Feb 1.

PMID:
30707661
7.

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.

Younes A, Brody J, Carpio C, Lopez-Guillermo A, Ben-Yehuda D, Ferhanoglu B, Nagler A, Ozcan M, Avivi I, Bosch F, Caballero Barrigón MD, Hellmann A, Kuss B, Ma DDF, Demirkan F, Yağci M, Horowitz NA, Marlton P, Cordoba R, Wrobel T, Buglio D, Streit M, Hodkinson BP, Schaffer M, Alvarez J, Ceulemans R, Balasubramanian S, de Jong J, Wang SS, Fourneau N, Jurczak W.

Lancet Haematol. 2019 Feb;6(2):e67-e78. doi: 10.1016/S2352-3026(18)30217-5. Epub 2019 Jan 11.

PMID:
30642819
8.

Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy.

Walewski J, Hellmann A, Siritanaratkul N, Ozsan GH, Ozcan M, Chuncharunee S, Goh AS, Jurczak W, Koren J, Paszkiewicz-Kozik E, Wang B, Singh S, Huebner D, Engert A, von Tresckow B.

Br J Haematol. 2018 Nov;183(3):400-410. doi: 10.1111/bjh.15539. Epub 2018 Aug 30.

PMID:
30168134
9.

Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients?

Atilla E, Yalciner M, Atilla PA, Ates C, Bozdag SC, Yuksel MK, Toprak SK, Gunduz M, Ozen M, Akan H, Demirer T, Arslan O, Ilhan O, Beksac M, Ozcan M, Gurman G, Topcuoglu P.

Antivir Ther. 2018;23(8):647-653. doi: 10.3851/IMP3252.

PMID:
29972137
10.

Upper respiratory viral infections in patients with haematological malignancies after allogeneic haematopoietic stem cell transplantation: a retrospective study.

Atilla E, Sahin D, Atilla PA, Dolapci I, Tekeli A, Bozdag SC, Yuksel MK, Toprak SK, Ilhan O, Arslan O, Ozcan M, Gurman G, Topcuoglu P.

Antivir Ther. 2018;23(6):523-527. doi: 10.3851/IMP3224.

PMID:
29424696
11.

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.

Dreyling M, Santoro A, Mollica L, Leppä S, Follows GA, Lenz G, Kim WS, Nagler A, Panayiotidis P, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Giurescu M, Cupit L, Liu L, Köchert K, Seidel H, Peña C, Yin S, Hiemeyer F, Garcia-Vargas J, Childs BH, Zinzani PL.

J Clin Oncol. 2017 Dec 10;35(35):3898-3905. doi: 10.1200/JCO.2017.75.4648. Epub 2017 Oct 4. Erratum in: J Clin Oncol. 2018 Feb 10;36(5):521.

PMID:
28976790
12.

Treatment with methotrexate, rituximab, and cytosine arabinoside followed by autologous stem cell transplantation in primary central nervous system lymphoma: A single-center experience.

Atilla PA, Atilla E, Bozdag SC, Yuksel MK, Toprak SK, Topcuoglu P, Demirer T, Ilhan O, Arslan O, Gurman G, Ozcan M.

Hematol Oncol Stem Cell Ther. 2018 Mar;11(1):13-17. doi: 10.1016/j.hemonc.2017.05.030. Epub 2017 Jun 15.

13.

Proper diagnosis of antithrombin III deficiency.

Narlı Özdemir Z, Özcan M.

Anatol J Cardiol. 2017 Apr;17(4):342. doi: 10.14744/AnatolJCardiol.2017.7693. No abstract available.

14.

Allogeneic hematopoietic stem cell transplantation for refractory mycosis fungoides (MF) and Sezary syndrome (SS).

Atilla E, Atilla PA, Bozdag SC, Yuksel MK, Toprak SK, Topcuoglu P, Akay BN, Sanli H, Gurman G, Ozcan M.

Int J Hematol. 2017 Sep;106(3):426-430. doi: 10.1007/s12185-017-2245-x. Epub 2017 May 2.

PMID:
28466385
15.

Subsequent malignancies after allogeneic hematopoietic stem cell transplantation.

Gündüz M, Özen M, Şahin U, Toprak SK, Civriz Bozdağ S, Kurt Yüksel M, Arslan Ö, Özcan M, Demirer T, Beksaç M, İlhan O, Gürman G, Topçuoğlu P.

Clin Transplant. 2017 Jul;31(7). doi: 10.1111/ctr.12987. Epub 2017 May 25.

PMID:
28432802
16.

The End of a Long Debate: Methylenetetrahydrofolate Reductase Gene Polymorphisms do not Increase Thrombosis Risk.

Sahin U, Ozcan M.

Eurasian J Med. 2017 Feb;49(1):76-77. doi: 10.5152/eurasianjmed.2017.16080. No abstract available.

17.

The Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study.

Tombak A, Uçar MA, Akdeniz A, Tiftik EN, Gören Şahin D, Akay OM, Yıldırım M, Nevruz O, Kis C, Gürkan E, Solmaz ŞM, Özcan MA, Yıldırım R, Berber İ, Erkurt MA, Fıratlı Tuğlular T, Tarkun P, Yavaşoğlu İ, Doğu MH, Sarı İ, Merter M, Özcan M, Yıldızhan E, Kaynar L, Mehtap Ö, Uysal A, Şahin F, Salim O, Sungur MA.

Turk J Haematol. 2016 Dec 1;33(4):273-280. doi: 10.4274/tjh.2015.0203. Epub 2016 Apr 18.

18.

Allogeneic Transplantation in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on Survival: A Quasi-Experimental Study.

Özen M, Üstün C, Öztürk B, Topçuoğlu P, Arat M, Gündüz M, Atilla E, Bolat G, Arslan Ö, Demirer T, Akan H, İlhan O, Beksaç M, Gürman G, Özcan M.

Turk J Haematol. 2017 Mar 1;34(1):16-26. doi: 10.4274/tjh.2015.0346. Epub 2016 Apr 18.

19.

A rare complication after allogeneic stem cell transplantation: post-transplant erythrocytosis.

Atilla E, Topcuoglu P, Ataca P, Pekcan G, Bozdag SC, Yuksel MK, Ozcan M, Gurman G, Toprak SK.

Clin Transplant. 2016 Jun;30(6):669-72. doi: 10.1111/ctr.12741. Epub 2016 May 2.

PMID:
27028115
20.

Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report.

Aylı M, Özcan M, Cengiz Seval G.

Turk J Haematol. 2015 Jun;32(2):180-3. doi: 10.4274/tjh.2013.0338.

Supplemental Content

Loading ...
Support Center